Solid Biosciences heads into its August 12 earnings print with short sellers rebuilding aggressively — yet the stock is up on the week, creating the week's central tension.
Short interest has become the defining story here. Bears have added hard in July: the short position has climbed 26.5% in one week and 30.6% over the past month, reaching 26.3% of the free float on 75.7 million shares available to borrow. That is a genuinely elevated level for a small-cap biotech. Yet the borrow market tells a different story from the headline number — availability is running at roughly 234%, meaning there are more than two shares available to borrow for every one already shorted. Cost to borrow has actually eased, falling roughly 19% on the week to just 0.52%. The lending pool is not squeezed. Bears are adding, but they face no friction doing so. The ORTEX short score has ticked to 70.3, its highest reading in the recent window, which reflects the rising short interest rather than any signal that a squeeze is building. Availability would need to tighten materially before that changes.
Options traders, by contrast, are leaning firmly bullish. The put/call ratio is running at 0.14, essentially flat with its 20-day average of 0.15 and well below the 52-week high of 5.0 — meaning calls are overwhelmingly dominant in the options market right now. This is the sharpest divergence in the current setup: short sellers are pressing harder even as options positioning stays constructively one-sided.
The Street remains solidly in the bull camp, though most recent target activity dates from late May and June. Eight analysts carry buy-equivalent ratings with no bears. JP Morgan's Anupam Rama lifted his Overweight target to $12 in March, Wedbush reiterated Outperform at $16 in May after trimming from $17, and HC Wainwright raised its Buy target to $25 in June. The mean consensus target sits at $17.73, roughly double the current price of $8.62. That gap is large enough to be treated with caution — it likely reflects the binary nature of gene therapy clinical data rather than near-term price expectations. The bull case centres on the SGT-003 Duchenne muscular dystrophy programme and a cash runway the company has guided into the first half of 2028. Bears point to execution risk in gene therapy delivery and competition from Sarepta Therapeutics in the DMD space. The price-to-book multiple has compressed roughly 22% over the past month, tracking the stock's 20% pullback in July.
BlackRock added 1.46 million shares in the quarter ending June 30, lifting its stake to 6.5% of shares outstanding — the largest institutional holder by a notable margin. Janus Henderson and Vanguard Capital both entered the register as new positions in the March quarter. The mix of passive and specialist biotech holders provides a reasonable institutional backstop, though Citadel trimmed slightly and Point72 reduced by 365,000 shares.
The earnings history offers limited comfort about direction. The four most recent prints produced moves of +9.9%, -0.6%, -3.9%, and +0.3% on the day — three of four were modest, with the May 12 release standing out for a -20.8% five-day follow-through. The next print on August 12 arrives with short interest near its highest level in months, an options market that is overwhelmingly positioned for upside, and a lending pool that remains loose enough to absorb more short selling. Whether clinical update language on SGT-003 or SGT-212 shifts that balance is the question worth tracking into the close of next week.
See the live data behind this article on ORTEX.
Open SLDB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
Solid Biosciences heads into its June 10 earnings report with an unusual split: short interest climbing while the Street grows more bullish. The earnings event is the lens through which everything else reads this week.…
Solid Biosciences heads into its May 19 quarterly report with shorts retreating from a recent peak yet the stock still carrying one of the more elevated short positions in the gene therapy space. Short sellers have…
